Albireo

Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders.

Morgan Prestwich is currently and exclusively retained under a Master Service Agreement (MSA) by Albireo to build their entire international launch operations.

- President International
- EU VP Medical Affairs
- EU Medical Director
- EU Snr Director Marketing
- VP Distributor Markets (Middle East, Africa, APAC)

In-country appointments:
- GM's - Germany, UK, France, Italy, Spain
- Medical Directors - Germany, UK, France, Italy, Spain
- Market Access, Germany, UK, France, Italy, Spain
- MSL's Germany, UK, France, Italy, Spain
- KAM's Germany, UK, France, Italy, Spain